Filing Details

Accession Number:
0000899243-21-022346
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-07 18:11:42
Reporting Period:
2021-06-03
Accepted Time:
2021-06-07 18:11:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1628171 Revolution Medicines Inc. RVMD () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1620014 Neil Exter C/O Third Rock Ventures, Llc
Newbury Street, 3Rd Floor
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-06-03 0 $0.00 0 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-04 0 $0.00 0 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 0 Indirect See footnotes
Common Stock 19,998 Direct
Common Stock 19,998 Indirect See footnote
Footnotes
  1. On June 3, 2021, Third Rock Ventures II, L.P. ("TRV II") sold 378,117 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $30.00 to $30.50, inclusive, at a weighted average price per share of $30.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
  2. After the above transaction, TRV II owned 164,996 shares of Common Stock of the Issuer.
  3. The Reporting Person is a partner of each of Third Rock Ventures GP II, L.P., TRV GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of TRV II, Third Rock Ventures III, L.P. ("TRV III") and Third Rock Ventures IV, L.P. ("TRV IV" and collectively with TRV II and TRV III, "the Funds"), respectively. The Reporting Person disclaims beneficial ownership over the shares held by the Funds, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
  4. On June 4, 2021, TRV II sold 164,996 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $30.10 to $30.76, inclusive, at a weighted average price per share of $30.23. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
  5. After the above transaction, TRV II owned 0 shares of Common Stock of the Issuer.
  6. TRV III directly holds 5,524,031 shares of Common Stock of the Issuer and TRV IV directly holds 1,419,900 shares of Common Stock of the Issuer.
  7. The shares are directly held in certain estate-planning trusts over which the Reporting Person may have voting and dispositive power. The Reporting Person disclaims beneficial ownership over the shares held by such trusts except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.